Betydning av variasjoner i østrogenomsetningen for behandlingseffekt samt risiko for brystkreft
- Prosjektnummer
- 911564
- Ansvarlig person
- Per Eystein Lønning
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Forskningsprosjekt
- Helsekategori
- Cancer
- Forskningsaktivitet
- 5. Treatment Developement
Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling.
NMR Biomed 2012 Feb;25(2):369-78. Epub 2011 aug 8
PMID: 21823183
Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia.
Oncogene 2012 Mar;31(12):1533-45. Epub 2011 aug 22
PMID: 21860418
Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women.
J Steroid Biochem Mol Biol 2012 Jan;128(1-2):69-75. Epub 2011 sep 16
PMID: 21939764
Vascular proliferation is a prognostic factor in breast cancer.
Breast Cancer Res Treat 2012 Jun;133(2):501-10. Epub 2011 sep 27
PMID: 21947750
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.
J Clin Oncol 2012 Mar;30(7):709-17. Epub 2011 okt 31
PMID: 22042946
SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.
Eur J Cancer 2012 Sep;48(13):1988-96. Epub 2011 nov 24
PMID: 22119201
Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.
BMC Cancer 2012;12():39. Epub 2012 jan 25
PMID: 22277092
Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer.
NMR Biomed 2012 Sep;25(9):1033-42. Epub 2012 jan 26
PMID: 22279038
Elevated levels of the steroidogenic factor 1 are associated with over-expression of CYP19 in an oestrogen-producing testicular Leydig cell tumour.
Eur J Endocrinol 2012 May;166(5):941-9. Epub 2012 feb 1
PMID: 22301800
P53 and its molecular basis to chemoresistance in breast cancer.
Expert Opin Ther Targets 2012 Mar;16 Suppl 1():S23-30. Epub 2012 feb 8
PMID: 22313396
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Breast Cancer Res 2012;14(2):R47. Epub 2012 mar 15
PMID: 22420423
MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk.
PLoS One 2012;7(4):e36263. Epub 2012 apr 30
PMID: 22558411
Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions.
Ther Adv Med Oncol 2012 May;4(3):127-37.
PMID: 22590486
Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension.
PLoS One 2012;7(6):e38364. Epub 2012 jun 15
PMID: 22719881
Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.
Breast Cancer Res 2012 Aug;14(4):R117. Epub 2012 aug 14
PMID: 22889108
Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers.
BMC Cancer 2012;12():454. Epub 2012 okt 5
PMID: 23039163
Chemosensitivity and p53; new tricks by an old dog.
Breast Cancer Res 2012 Nov;14(6):325. Epub 2012 nov 6
PMID: 23131146
[Genome sequencing for personalized cancer treatment].
Tidsskr Nor Laegeforen 2012 Nov;132(21):2406-8.
PMID: 23160594
Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
Biochim Biophys Acta 2013 Mar;1830(3):2790-7.
PMID: 23246812
Alterations of the retinoblastoma gene in metastatic breast cancer.
Clin Exp Metastasis 2011 Mar;28(3):319-26. Epub 2011 jan 21
PMID: 21253829
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.
Cancer Cell 2011 Feb;19(2):273-82.
PMID: 21316605
RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer.
Ann Oncol 2011 Oct;22(10):2208-15. Epub 2011 feb 16
PMID: 21325450
10th International Aromatase Conference Proceedings, September 2010. Preface.
Steroids 2011 Jul;76(8):729. Epub 2011 mar 23
PMID: 21414335
MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk.
Oncotarget 2011 Mar;2(3):251-8.
PMID: 21436469
Recent data on intratumor estrogens in breast cancer.
Steroids 2011 Jul;76(8):786-91. Epub 2011 mar 31
PMID: 21439992
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
PLoS One 2011;6(4):e19249. Epub 2011 apr 27
PMID: 21556366
Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer.
Br J Cancer 2011 Jun;105(1):9-12. Epub 2011 jun 14
PMID: 21673677
Hospital volume and prognosis among Norwegian breast cancer patients enrolled in adjuvant trials.
Acta Oncol 2011 Oct;50(7):1068-74. Epub 2011 jul 11
PMID: 21745131
Exploring breast cancer estrogen disposition: the basis for endocrine manipulation.
Clin Cancer Res 2011 Aug;17(15):4948-58. Epub 2011 jul 26
PMID: 21791635
Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk.
Transcription 2011 Sep-Oct;2(5):207-10.
PMID: 22231115
Are current development programs realising the full potential of new agents?
Breast Cancer Res 2010;12 Suppl 4():S23. Epub 2010 des 20
PMID: 21172086
Session 6 introduction.
Breast Cancer Res 2010;12 Suppl 4():S15. Epub 2010 des 20
PMID: 21172077
Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter.
Cancer Res 2010 Aug;70(15):6393-6. Epub 2010 jul 14
PMID: 20631079
Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers.
Mol Cancer 2010;9():173. Epub 2010 jul 1
PMID: 20594292
MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.
Eur J Cancer 2010 Jul;46(11):2127-33. Epub 2010 jun 10
PMID: 20541396
Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine.
J Invest Dermatol 2010 Oct;130(10):2514-6. Epub 2010 mai 27
PMID: 20505745
Molecular basis for therapy resistance.
Mol Oncol 2010 Jun;4(3):284-300. Epub 2010 apr 24
PMID: 20466604
Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.
Clin Cancer Res 2010 Jul;16(13):3356-67. Epub 2010 mai 11
PMID: 20460471
Evolution of endocrine adjuvant therapy for early breast cancer.
Expert Opin Investig Drugs 2010 Apr;19 Suppl 1():S19-30.
PMID: 20374026
DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.
Mol Cancer 2010;9():68. Epub 2010 mar 25
PMID: 20338046
Intratumoral estrogen disposition in breast cancer.
Clin Cancer Res 2010 Mar;16(6):1790-801. Epub 2010 mar 9
PMID: 20215536
Endocrine effects of aromatase inhibitors.
J Clin Oncol 2010 Feb;28(6):e101-2; author reply e103-4. Epub 2010 jan 19
PMID: 20085930
Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity.
Biochim Biophys Acta 2010 Mar;1803(3):386-95. Epub 2010 jan 15
PMID: 20080130
Breast cancer aromatase expression evaluated by the novel antibody 677: correlations to intra-tumor estrogen levels and hormone receptor status.
J Steroid Biochem Mol Biol 2010 Feb;118(4-5):237-41. Epub 2009 okt 31
PMID: 19883757
Impact of aromatase inhibitors on bone health in breast cancer patients.
J Steroid Biochem Mol Biol 2010 Feb;118(4-5):294-9. Epub 2009 okt 13
PMID: 19833206
Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: of relevance to clinical understanding?
J Steroid Biochem Mol Biol 2010 Feb;118(4-5):288-93. Epub 2009 okt 4
PMID: 19808096
Role of molecular markers in breast cancer therapy
Chinese J of Breast Disease 4:1-7,2010
cand scient
- Disputert:
- oktober 2012
- Hovedveileder:
- Per E lønning
Chemotherapy resistance in breast cancer : the potential role of Chk2 splice variants an RB1 alterations
- Disputert:
- november 2010
- Hovedveileder:
- Per Eystein Lønning
Genetic biomarkers as prognostic and predictive factors in metastatic malignant melanoma
- Disputert:
- oktober 2010
- Hovedveileder:
- Per Eystein Lønning
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest